Pieris Pharmaceuticals Inc (PIRS): Rasio rega marang dodolan

Logo korporat perusahaan Pieris Pharmaceuticals Inc (PIRS)

Pieris Pharmaceuticals (PIRS) aims for the global implementation of Anticalin protein technologies to combat cancer and lung diseases, while the P/S ratio history is available for analysis on GURU.Markets, where the 821.20 level serves as a critical benchmark. The current restructuring following the dissolution of major alliances requires strict regulatory oversight, and development relies on attracting leading biologists through competitive salaries.

Pieris (PIRS): Multiplikator P/S saka 04.07.2022 nganti 31.12.2025

Rincian analitis perusahaan Pieris (PIRS)

- rega saham lan konsensus proyeksi valuasi:
Bagan owah-owahan rega pieris.com|PIRS - Bagan rega target
- data kapitalisasi bursa:
Biji pasar Pieris|PIRS - Nilai Perusahaan
- indikator nilai aset resik miturut neraca:
Aset Bersih saben Saham Pieris Pharmaceuticals|PIRS - Kapitalisasi Buku|Koefisien Nilai Pasar marang Nilai Buku pieris.com|PIRS - Aset Agregat Perusahaan
- statistik kawajiban utang lan likuiditas:
Rasio Kabeh Utang marang Dana Pribadi Pieris Pharmaceuticals|PIRS - Utang jangka dawa marang modal|Koefisien utang jangka cendhak marang modal Pieris Pharma|PIRS - Utang perusahaan|Utang-utang marang aset resik Pieris|PIRS - Kewajiban jangka dawa perusahaan|Silihan lan utang jangka cendhak perusahaan Pieris Pharmaceuticals|Rasio likuiditas kritis pieris.com
- data bathi resik lan rasio valuasi:
PIRS - Bathi resik|Penghasilan resik sing dikarepake Pieris Pharmaceuticals|PIRS - Pangali P/E|Pangali Forward P/E Pieris Pharmaceuticals Inc|PIRS - Rasio rega marang bathi tumrap wutah|Nilai bisnis marang bathi operasional sadurunge panyusutan Pieris|PIRS - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|Bathi resik saben saham sajrone 12 wulan pungkasan Pieris Pharmaceuticals|PIRS - Bathi resik saben saham (EPS TTM)|Wutah bathi EPS kuartalan pieris.com|PIRS - Wutah bathi ing taun lumaku|Prakiraan wutah bathi saben saham kanggo taun ngarep Pieris Pharmaceuticals
- rincian pendapatan lan dodolan emiten:
PIRS - Pendapatan lan volume dodolan|Volume dodolan sing dikarepake perusahaan pieris.com|PIRS - Kapitalisasi marang pendapatan|Multiplikator Forward P/S Pieris
Analisis fundamental perusahaan:PIRS, pieris.com
Produk dadi Pieris Pharmaceuticals

Evaluating market value relative to generated income is critical for selecting assets with a high margin of safety. This price-to-sales ratio correlates the market capitalization of Pieris Pharmaceuticals (PIRS) with licensing revenue from anti-calin proteins and royalties from AstraZeneca and Servier, allowing investors to determine the premium paid for innovative drug potential by analyzing the historical trend of this metric.

Karo sapa Pieris Pharmaceuticals saingan

HLN (haleon.com) - Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan Kenvue KVUE|VRNA (Verona Pharma PLC) - Rasio rega marang dodolan|Jyong Biotech Corp - Multiplikator P/S|Koefisien rega marang pendapatan Ligand Corp LGND|AMRX: Multiplikator P/S|Rega marang dodolan perrigo.com (PRGO)|Rasio rega marang pendapatan Alvotech SA|LQDA: Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S GLPG|Koefisien rega marang pendapatan ANI Pharmaceuticals Corp|Rasio rega marang pendapatan MannKind Corporation MNKD|Koefisien rega marang pendapatan amphastar.com (AMPH)|PCRX: Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan SPRY (ARS Pharmaceuticals Inc)|Theravance (TBPH) - Rasio rega marang pendapatan|Rasio rega marang dodolan AQST (Aquestive Corp)|SCPH (scPharmaceuticals, Inc.) - Multiplikator P/S|TECX: Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S TNXP|Multiplikator P/S sxtchina.com (SXTC)|Rasio rega marang pendapatan Eupraxia Pharmaceuticals Inc. EPRX|Rasio kapitalisasi pasar marang pendapatan BHST|EXOZ - Rasio rega marang pendapatan|Oramed Pharmaceuticals (ORMP) - Kapitalisasi marang pendapatan|ENTX: Multiplikator P/S|MindWalk Holdings, Inc. (HYFT) - Multiplikator P/S|ABVC (ABVC BioPharma Inc) - Multiplikator P/S|Kapitalisasi marang pendapatan Cumberland Corp (CPIX)|Multiplikator P/S QNTM|FGEN - Rega marang dodolan|Telomir Pharmaceuticals, Inc. - Kapitalisasi marang pendapatan|Multiplikator P/S Rani Therapeutics Holdings RANI|SNYR: Kapitalisasi marang pendapatan|Rallybio Corporation - Kapitalisasi marang volume dodolan|LEXX: Multiplikator P/S|PULM - Koefisien rega marang pendapatan|PTHL (Pheton Holdings Limited) - Multiplikator P/S|Kapitalisasi marang pendapatan Aptorum (APM)|Multiplikator P/S LYRA|Multiplikator P/S Impact BioMedical, Inc. (IBO)|Rasio rega marang pendapatan TNF Pharmaceuticals, Inc. TNFA|cbdMD Inc. - Rasio rega marang pendapatan|PRFX - Rasio rega marang pendapatan|Koefisien rega marang pendapatan Altamira Therapeutics CYTO|Lipella (LIPO) - Rasio rega marang pendapatan|Rasio rega marang dodolan OPTN (OptiNose Corp)|PROC (Procaps Group S.A.) - Multiplikator P/S|petrospharma.com (PTPI) - Koefisien rega marang pendapatan|Rasio rega marang pendapatan Qilian International Holding (QLI)|SLRN (Acelyrin Inc.) - Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan TFF Pharma TFFP